🚀 VC round data is live in beta, check it out!
Vaxcell-Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vaxcell-Bio and similar public comparables like Equillium, Prestige Biologics, AN2 Therapeutics, Oncolytics Biotech and more.
Vaxcell-Bio Overview
About Vaxcell-Bio
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.
Founded
2010
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$113M
Vaxcell-Bio Financials
Vaxcell-Bio reported last fiscal year revenue of $5M and negative EBITDA of ($7M).
In the same fiscal year, Vaxcell-Bio generated $609K in gross profit, ($7M) in EBITDA losses, and had net loss of ($9M).
Vaxcell-Bio P&L
In the most recent fiscal year, Vaxcell-Bio reported revenue of $5M and EBITDA of ($7M).
Vaxcell-Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $609K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (155%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (220%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (189%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vaxcell-Bio Stock Performance
Vaxcell-Bio has current market cap of $129M, and enterprise value of $113M.
Market Cap Evolution
Vaxcell-Bio's stock price is $5.56.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $129M | 0.0% | XXX | XXX | XXX | $-0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVaxcell-Bio Valuation Multiples
Vaxcell-Bio trades at 23.5x EV/Revenue multiple, and (15.2x) EV/EBITDA.
Vaxcell-Bio Financial Valuation Multiples
As of April 19, 2026, Vaxcell-Bio has market cap of $129M and EV of $113M.
Equity research analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vaxcell-Bio has a P/E ratio of (14.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $129M | XXX | $129M | XXX | XXX | XXX |
| EV (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 23.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (15.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (10.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 185.8x | XXX | XXX | XXX |
| P/E | — | XXX | (14.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vaxcell-Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vaxcell-Bio Margins & Growth Rates
Vaxcell-Bio's revenue in the last fiscal year grew by 272%.
Vaxcell-Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 272% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (155%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 22% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 80% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 232% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vaxcell-Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vaxcell-Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Equillium | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| AN2 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncolytics Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunic | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vaxcell-Bio M&A Activity
Vaxcell-Bio acquired XXX companies to date.
Last acquisition by Vaxcell-Bio was on XXXXXXXX, XXXXX. Vaxcell-Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vaxcell-Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVaxcell-Bio Investment Activity
Vaxcell-Bio invested in XXX companies to date.
Vaxcell-Bio made its latest investment on XXXXXXXX, XXXXX. Vaxcell-Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vaxcell-Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vaxcell-Bio
| When was Vaxcell-Bio founded? | Vaxcell-Bio was founded in 2010. |
| Where is Vaxcell-Bio headquartered? | Vaxcell-Bio is headquartered in South Korea. |
| Who is the CEO of Vaxcell-Bio? | Vaxcell-Bio's CEO is Je-jung Lee. |
| Is Vaxcell-Bio publicly listed? | Yes, Vaxcell-Bio is a public company listed on Korea Exchange. |
| What is the stock symbol of Vaxcell-Bio? | Vaxcell-Bio trades under 323990 ticker. |
| When did Vaxcell-Bio go public? | Vaxcell-Bio went public in 2020. |
| Who are competitors of Vaxcell-Bio? | Vaxcell-Bio main competitors are Equillium, Prestige Biologics, AN2 Therapeutics, Oncolytics Biotech. |
| What is the current market cap of Vaxcell-Bio? | Vaxcell-Bio's current market cap is $129M. |
| What is the current revenue of Vaxcell-Bio? | Vaxcell-Bio's last fiscal year revenue is $5M. |
| What is the current EV/Revenue multiple of Vaxcell-Bio? | Current revenue multiple of Vaxcell-Bio is 23.5x. |
| Is Vaxcell-Bio profitable? | No, Vaxcell-Bio is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.